A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia (NCT07709832) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia
China34 participantsStarted 2026-07-31
Plain-language summary
The goal of this clinical trial is to learn if an autostereoscopic 3D amblyopia training system works to improve vision in children and adolescents with amblyopia. It will also learn about the safety and tolerability of the 3D training system. The main questions it aims to answer are:
* Does autostereoscopic 3D vision training improve best corrected visual acuity in the amblyopic eye compared to conventional patching therapy?
* What side effects or discomfort do participants experience during 3D training versus patching? Researchers will compare the autostereoscopic 3D training system to conventional daily eye patching to see which treatment works better for improving vision in amblyopia.
Participants will:
* Be randomly assigned to either the 3D training group or the patching group
* Complete daily home treatment for 6 months - either 20 minutes of 3D vision training or 2 hours of continuous eye patching
* Visit the clinic at baseline, 1 month, 3 months, and 6 months for eye exams and vision tests
* Have their treatment progress monitored remotely through training data logs or patching diaries
Who can participate
Age range
7 Years – 12 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Unilateral amblyopia (anisometropic, strabismic, or ametropic)
* Age: 7 to 12 years
* Amblyopic eye BCVA: 0.1 to 0.8 LogMAR
* Fellow eye BCVA: ≥ 0.8 LogMAR
* Stable refractive status (≤ ±0.50D change in past 6 months)
* Written informed consent from participant and guardian
Exclusion Criteria:
* Deprivation amblyopia (congenital cataract, ptosis, etc.)
* Organic ocular disease (glaucoma, retinopathy, optic neuropathy)
* Previous ocular surgery or trauma
* Severe dry eye or other ocular surface disorders
* Uncontrolled systemic diseases (diabetes, hypertension)
* Neuropsychiatric conditions preventing cooperation
* Participation in other clinical trials within 3 months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.